Cardiff Garcia
Cardiff Garcia is a co-host of NPR's The Indicator from Planet Money podcast, along with Stacey Vanek Smith. He joined NPR in November 2017.
Previously, Garcia was the U.S. editor of FT Alphaville, the flagship economics and finance blog of the Financial Times, where for seven years he wrote and edited stories about the U.S. economy and financial markets. He was also the founder and host of FT Alphachat, the Financial Times' award-winning business and economics podcast.
As a guest commentator, he has regularly appeared on media outlets such as Marketplace Radio, WNYC, CNBC, Yahoo Finance, the BBC, and others.
-
We've heard a lot about how hard it's been for restaurants to stay open during the pandemic. But what we often don't hear is that closing can be just as tough.
-
The coronavirus has been responsible for massive business closures, but figures show Americans are still starting businesses at the fastest rate in more than a decade.
-
The first doses of COVID-19 vaccines are being administered. Our Planet Money team delves into the dark web to learn more about the counterfeit vaccines that are being sold around the world.
-
Each year, The American Farm Bureau estimates the cost of Thanksgiving dinner. The most shocking finding this year? Thanksgiving dinner is the cheapest it's been since the survey started 35 years ago.
-
News of the Pfizer COVID-19 vaccine's effectiveness has inspired hope around containing the coronavirus. But polls show that up to two-thirds of Americans say they are unlikely to get a vaccine.
-
Of the 1.1 million people who left the job market in September, more than 860,000 were women. We examine why women are dropping out of the workforce, and what it will mean for the economy.
-
The coronavirus pandemic forced many people to work from home. NPR looks into what remote work from home could mean for commercial real estate.
-
It seems everyone wants to develop a coronavirus vaccine. But vaccine development usually takes years. The White House is betting money can speed things up.
-
Governments and drug companies agree there is an urgency to develop a vaccine for COVID-19. But their motives for developing it are different — and it might hugely affect the vaccine's price.
-
The coronavirus crisis has left many companies with huge budget shortfalls and some have turned to borrowing. There is a new strategy that some companies have adopted to control their debt.